Beneficio Operativo Cambio Fecha
Adma Biologics USD 50.29M 12.46M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Novavax USD 20.94M 100.32M 2025-12
Omeros USD -35.41M 23.75M 2024-09
Takeda JPY 201.42B 215.04B 2026-06